258 related articles for article (PubMed ID: 36878753)
21. Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases.
Heidenreich A; Fossati N; Pfister D; Suardi N; Montorsi F; Shariat S; Grubmüller B; Gandaglia G; Briganti A; Karnes RJ
Eur Urol Oncol; 2018 May; 1(1):46-53. PubMed ID: 31100228
[TBL] [Abstract][Full Text] [Related]
22. Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis.
Glicksman RM; Metser U; Vines D; Valliant J; Liu Z; Chung PW; Bristow RG; Finelli A; Hamilton R; Fleshner NE; Perlis N; Zlotta AR; Green D; Bayley A; Helou J; Raman S; Kulkarni G; Catton C; Lam T; Chan R; Warde P; Gospodarowicz M; Jaffray DA; Berlin A
Eur Urol; 2021 Sep; 80(3):374-382. PubMed ID: 33685838
[TBL] [Abstract][Full Text] [Related]
23. Natural History of Clinical Recurrence Patterns of Lymph Node-Positive Prostate Cancer After Radical Prostatectomy.
Moschini M; Sharma V; Zattoni F; Quevedo JF; Davis BJ; Kwon E; Karnes RJ
Eur Urol; 2016 Jan; 69(1):135-42. PubMed ID: 25865061
[TBL] [Abstract][Full Text] [Related]
24. Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial.
Ost P; Reynders D; Decaestecker K; Fonteyne V; Lumen N; De Bruycker A; Lambert B; Delrue L; Bultijnck R; Claeys T; Goetghebeur E; Villeirs G; De Man K; Ameye F; Billiet I; Joniau S; Vanhaverbeke F; De Meerleer G
J Clin Oncol; 2018 Feb; 36(5):446-453. PubMed ID: 29240541
[TBL] [Abstract][Full Text] [Related]
25. Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study.
Steuber T; Budäus L; Walz J; Zorn KC; Schlomm T; Chun F; Ahyai S; Fisch M; Sauter G; Huland H; Graefen M; Haese A
BJU Int; 2011 Jun; 107(11):1755-61. PubMed ID: 20942833
[TBL] [Abstract][Full Text] [Related]
26. Extended Results and Independent Validation of a Phase 2 Trial of Metastasis-Directed Therapy for Molecularly Defined Oligometastatic Prostate Cancer.
Glicksman RM; Ramotar M; Metser U; Chung PW; Liu Z; Vines D; Finelli A; Hamilton R; Fleshner NE; Perlis N; Zlotta AR; Bayley A; Helou J; Raman S; Kulkarni G; Catton C; Lam T; Chan R; Warde P; Gospodarowicz M; Jaffray DA; Berlin A
Int J Radiat Oncol Biol Phys; 2022 Nov; 114(4):693-704. PubMed ID: 36031465
[TBL] [Abstract][Full Text] [Related]
27. Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years.
Suardi N; Gandaglia G; Gallina A; Di Trapani E; Scattoni V; Vizziello D; Cucchiara V; Bertini R; Colombo R; Picchio M; Giovacchini G; Montorsi F; Briganti A
Eur Urol; 2015 Feb; 67(2):299-309. PubMed ID: 24571959
[TBL] [Abstract][Full Text] [Related]
28. Which Patients with Clinically Node-positive Prostate Cancer Should Be Considered for Radical Prostatectomy as Part of Multimodal Treatment? The Impact of Nodal Burden on Long-term Outcomes.
Gandaglia G; Soligo M; Battaglia A; Muilwijk T; Robesti D; Mazzone E; Barletta F; Fossati N; Moschini M; Bandini M; Joniau S; Karnes RJ; Montorsi F; Briganti A
Eur Urol; 2019 May; 75(5):817-825. PubMed ID: 30409676
[TBL] [Abstract][Full Text] [Related]
29. Cohort Study of Oligorecurrent Prostate Cancer Patients: Oncological Outcomes of Patients Treated with Salvage Lymph Node Dissection via Prostate-specific Membrane Antigen-radioguided Surgery.
Knipper S; Mehdi Irai M; Simon R; Koehler D; Rauscher I; Eiber M; van Leeuwen FWB; van Leeuwen P; de Barros H; van der Poel H; Budäus L; Steuber T; Graefen M; Tennstedt P; Heck MM; Horn T; Maurer T
Eur Urol; 2023 Jan; 83(1):62-69. PubMed ID: 35718637
[TBL] [Abstract][Full Text] [Related]
30. Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy.
De Bleser E; Jereczek-Fossa BA; Pasquier D; Zilli T; Van As N; Siva S; Fodor A; Dirix P; Gomez-Iturriaga A; Trippa F; Detti B; Ingrosso G; Triggiani L; Bruni A; Alongi F; Reynders D; De Meerleer G; Surgo A; Loukili K; Miralbell R; Silva P; Chander S; Di Muzio NG; Maranzano E; Francolini G; Lancia A; Tree A; Deantoni CL; Ponti E; Marvaso G; Goetghebeur E; Ost P
Eur Urol; 2019 Dec; 76(6):732-739. PubMed ID: 31331782
[TBL] [Abstract][Full Text] [Related]
31. Stereotactic Radiotherapy for Lesions Detected via
Pan J; Wei Y; Zhang T; Liu C; Hu X; Zhao J; Gan H; Liu W; Zhu B; Wu J; Wang B; Song S; Ye D; Zhu Y
Eur Urol Oncol; 2022 Aug; 5(4):420-427. PubMed ID: 35304107
[TBL] [Abstract][Full Text] [Related]
32. Impact of Early Salvage Androgen Deprivation Therapy in Localized Prostate Cancer after Radical Prostatectomy: A Propensity Score Matched Analysis.
Park JW; Jang WS; Koh DH; Ham WS; Rha KH; Hong SJ; Choi YD
Yonsei Med J; 2018 Jul; 59(5):580-587. PubMed ID: 29869455
[TBL] [Abstract][Full Text] [Related]
33. Management of positive lymph nodes following radical prostatectomy.
Heidenreich A; Rieke M; Mahjoub S; Pfister D
Arch Esp Urol; 2019 Mar; 72(2):182-191. PubMed ID: 30855020
[TBL] [Abstract][Full Text] [Related]
34. Mid-term Outcomes Following Salvage Lymph Node Dissection for Prostate Cancer Nodal Recurrence Status Post-radical Prostatectomy.
Zattoni F; Nehra A; Murphy CR; Rangel L; Mynderse L; Lowe V; Kwon E; Karnes RJ
Eur Urol Focus; 2016 Dec; 2(5):522-531. PubMed ID: 28723518
[TBL] [Abstract][Full Text] [Related]
35. Long-term outcomes of patients with lymph node metastasis treated with radical prostatectomy without adjuvant androgen-deprivation therapy.
Touijer KA; Mazzola CR; Sjoberg DD; Scardino PT; Eastham JA
Eur Urol; 2014 Jan; 65(1):20-5. PubMed ID: 23619390
[TBL] [Abstract][Full Text] [Related]
36. Safety and efficiency of repeat salvage lymph node dissection for recurrence of prostate cancer using PSMA-radioguided surgery (RGS) after prior salvage lymph node dissection with or without initial RGS support.
Falkenbach F; Knipper S; Koehler D; Ambrosini F; Steuber T; Graefen M; Budäus L; Eiber M; Lunger L; Lischewski F; Heck MM; Maurer T
World J Urol; 2023 Sep; 41(9):2343-2350. PubMed ID: 37515651
[TBL] [Abstract][Full Text] [Related]
37. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
[TBL] [Abstract][Full Text] [Related]
38. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
39. Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy.
Fossati N; Karnes RJ; Cozzarini C; Fiorino C; Gandaglia G; Joniau S; Boorjian SA; Goldner G; Hinkelbein W; Haustermans K; Tombal B; Shariat S; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T; Briganti A
Eur Urol; 2016 Apr; 69(4):728-733. PubMed ID: 26497924
[TBL] [Abstract][Full Text] [Related]
40. OLIGOPELVIS GETUG P07, a Multicenter Phase II Trial of Combined High-dose Salvage Radiotherapy and Hormone Therapy in Oligorecurrent Pelvic Node Relapses in Prostate Cancer.
Supiot S; Vaugier L; Pasquier D; Buthaud X; Magné N; Peiffert D; Sargos P; Crehange G; Pommier P; Loos G; Hasbini A; Latorzeff I; Silva M; Denis F; Lagrange JL; Morvan C; Campion L; Blanc-Lapierre A
Eur Urol; 2021 Oct; 80(4):405-414. PubMed ID: 34247896
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]